CFM-2 NEW
| Price | $54 | $88 | Get Latest Price |
| Package | 5mg | 10mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: CFM-2 | CAS No.: 178616-26-7 |
| Purity: 97.16% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | CFM-2 |
| Description | CFM-2, a potent and selective non-competitive antagonist of AMPAR (AMPAR), exhibits anticonvulsant activity across various seizure models. |
| In vitro | CFM-2 inhibits the extracellular signal-regulated kinase (ERK1/2) pathway, reduces phosphorylation of cAMP-responsive element-binding protein (CREB), and suppresses cyclin D1 expression. It upregulates cell cycle regulators and tumor suppressor proteins p21 and p53, consequently decreasing lung adenocarcinoma cell populations in the G2 and S phases of the cell cycle. |
| In vivo | Pretreatment with CFM-2 delayed the progression of seizure rank during repeated administration of pentylenetetrazole. At the end of the period of repeated pentylenetetrazole treatment (6 weeks), the mean seizure score was 0 in vehicle-treated controls, 4.3 in animals treated with vehicle + pentylenetetrazole, 2.2 in rats treated chronically with CFM-2 (20 μmol/kg i.p.) + pentylenetetrazole and 1.0 in rats treated repeatedly with CFM-2 (50 μmol/kg i.p.) + pentylenetetrazole. CFM-2 was also able to antagonize the long-term increase in sensitivity of the convulsant effects of GABA function inhibitors in pentylenetetrazole-kindled animals [1]. CFM-2 has been proven to possess anticonvulsant activity in various models of seizures [2]. Intrathecal application of two selective non-competitive AMPAR antagonists, CFM-2 (25 and 50 μg) and GYKI 52466 (50 μg), significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at 2 and 24 h post-CFA injection. Neither CFM-2 nor GYKI 52466 affected the contralateral basal responses to thermal and mechanical stimuli [4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (144.54 mM), Sonication is recommended. |
| Keywords | CFM2 | CFM 2 | CFM-2 |
| Inhibitors Related | (-)-Aspartic acid | Mephenesin | Quinolinic acid | Decanoic Acid | L-Glutamic acid | Omberacetam | glycine | L-Glutamic acid monosodium salt | D-Cycloserine | Piracetam | Linalool | Memantine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $293.00/1mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-13 | |
| $36.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-13 | |
| $20.00/1kg |
VIP2Y
|
Hebei Miaoyin Technology Co.,Ltd
|
2023-04-04 | |
| $0.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY